Beta-Blocker Heart Attack Trial (BHAT)

Summary

To determine whether the regular administration of the beta-blocker drug propranolol to people who had had at least one documented myocardial infarction would result in a significant reduction of mortality from all causes over the follow-up period. Eligible volunteer patients were recruited to participate in a double-blind clinical trial within 21 days after the onset of the acute event. One-half of the patients were randomly assigned to a beta-blocking drug (propranolol) and one-half to a placebo. The trial also evaluated the effect of propranolol on incidences of coronary heart disease mortality, sudden cardiac death, and nonfatal myocardial infarction plus coronary heart disease mortality in persons with documented previous myocardial infarction.

Conditions

• Arrhythmia
• Cardiovascular Diseases
• Coronary Disease
• Death, Sudden, Cardiac
• Heart Diseases
• Myocardial Infarction
• Myocardial Ischemia
• Ventricular Fibrillation

Interventions

DRUG

propranolol

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

  lead NIH

Principal Investigators

• Allan Barker · Salt Lake Clinic Research Foundation

• Nemat Borhani · University of California, Davis

• Gerald Breneman · Henry Ford Hospital

• Frank Canosa · Miami Heart Institute

• Robert Capone · Rhode Island Hospital

• Richard Crow · University of Minnesota

• Alan Forker (participated until Feb · University of Nebraska

• Peter Gazes · University of South Carolina

• John Gregory · Atlantic Health System

• John Grover · Kaiser Foundation Research Institute

• Olga Haring · Northwestern University

• Julian Haywood · University of Southern California

• William Holmes · Lankenau Hospital

• Frank Ibbott · Bio-Science Laboratories

• Robert Kohn · State University of New York

• Robert Kramer · Long Island Jewish-Hillside Medical Center

• Peter Kuo · New Jersey College of Medicine and Dentistry-Rutgers

• Charles Laubach · Geisinger Clinic

• Edgar Lichstein · Maimonides Medical Center

• Louis Matthews · Dartmouth-Hitchcock Medical Center

• Gordon Maurice · Providence Medical Center

• J. McNamara · Pacific Health Research Institute

• E. Michau · Veterans Administration Hospital

• Richard Miller · Baylor College of Medicine

• Joel Morganroth · Anthropometrics Heart Clinic

• Marvin Murphy

• Robert Peters · University of California

• Thaddeus Prout · Greater Baltimore Medical Center

• Phillip Ranheim · MOUNT SINAI HOSPITAL

• David Richardson · Medical College of Virginia

• Robert Schlant · Emory University

• James Schoenberger · Rush-Presbyterian-St.Luke's Hospital

• Pierre Theroux · Montreal Heart Institute

• Pantel Vokonas · Boston University

• James Walsh · Veterans Administration Hospital

• Gary Wilner · Endeavor Health

• Paul Yu · University of Rochester

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Eligibility

Min Age

30 Years

Max Age

69 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1977-09-30

Completion

1981-10-31